News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Jean-Charles Soria discusses MSI-H and ICI response in cancer treatment
Jean-Charles Soria/LinkedIn
May 6, 2025, 18:15

Jean-Charles Soria discusses MSI-H and ICI response in cancer treatment

Jean-Charles Soria, SVP and Oncology Therapeutic Area Head of Amgen, shared a post on LinkedIn:

“MSI-H = hallmark of mismatch repair (MMR) deficiency.
Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric.
But not all MSI-H/dMMR tumors are alike:
1.MSH2/MSH6 loss → ↑ TMB, better ICI response
2.PTEN/AKT1 mutations → ICI resistance
Checkpoint blockade is now 1L in CRC and endometrial.”

Jean-Charles Soria

Title: Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers

Journal: Nature Reviews Clinical Oncology

Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio

Read the full article.

Jean-Charles Soria

More posts featuring Jean-Charles Soria on OncoDaily.

cancer Carolina Sciortino Filippo Ghelardi Filippo Pietrantonio Jean-Charles Soria Jenny F. Seligmann Julien Taieb Margherita Ambrosini OncoDaily Oncology Paolo Manca Vincenzo Nasca
Special Coverage
Blog
May 29, 2025, 16:16
From Targeted Therapies to Early Detection, Connect With SCRI at ASCO25 - Sarah Cannon Research Institute
Blog
May 29, 2025, 15:41
Meet The Translational and Therapeutic Research in Pancreatic Cancer Team at Cancer Research Centre of Marseille - AFRCP
Career
May 29, 2025, 15:32
Join University of Arizona Cancer Center at ASCO 2025 to Explore Oncology Job Opportunities
Blog
May 29, 2025, 15:10
FORwards Special Interest Group Webinar on Fear of Cancer Recurrence Featuring Expert Christine Maheu
Blog
May 29, 2025, 14:19
Anna Cabanes on ATOM Coalition's Milestone in Global Cancer Access Program at the Recent Workshop in Zambia
Insight
May 29, 2025, 14:15
New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer
Opinion
May 29, 2025, 13:47
Robin Zon and Andy Guinigundo Highlighted the Importance of Team Attendance at ASCO 2025
Blog
May 29, 2025, 13:35
Habib Nehmé Highlights Elekta’s Record Fourth Quarter and Global Teamwork
Opinion
May 29, 2025, 13:32
List of 10 ADC Presentations Not to Miss at the ASCO 2025 Curated by Paolo Tarantino and Raffaele Colombo
Blog
May 29, 2025, 13:16
Dana Bryson Highlights ACT for Children's Progress in Expanding Pediatric Cancer Access
Insight
May 29, 2025, 13:11
START and OneOncology Partner to Expand Access to Early-Phase Oncology Trials
Blog
May 29, 2025, 13:01
Ruben Mesa: Wonderful panel at CancerX by members of our Advocate Health Cancer National Service Line